Decontamination of Open Wounds - Open Topic

Closed Solicitation Posted

Solicitation number
CBD234-P001
Agency
Responses due
Set-aside
Total Small Business

Opportunity facts

More information

Notice details come from DoD SBIR/STTR (DSIP). Updated .

About this opportunity

The Department of the Army Acquisition Support Center's Joint PEO Chemical and Biological Defense seeks Phase I SBIR proposals under open topic CBD234-P001, Decontamination of Open Wounds, with proposals due November 14, 2023, a deadline that passed before the current date of November 17, 2026. The set-aside is Total Small Business. Each small business may submit one proposal per open topic, and multiple submissions result in only the most recent being evaluated.

Proposals must be submitted electronically through the Defense SBIR/STTR Innovation Portal (DSIP). Topic Q&A closed October 31, 2023. The topic seeks a man-portable capability that rapidly removes chemical warfare agents and toxic industrial chemicals from intact and wounded human skin under austere conditions without harming the skin or wound. Stated requirements include simplicity of field use, light weight and compact stowage, effectiveness across a wide range of environmental conditions, FDA compliance, long shelf-life, ease of transportation and manufacturability, cost-effectiveness, and in-situ detoxification to prevent agent diffusion into sub-dermal regions and secondary contamination.

Phase I is a feasibility study with a funding cap of $197,283.00 and a period of performance of up to six months. Phase II prototype development is limited to Phase I awardees, may be submitted no sooner than five months after Phase I award, and carries a 24-month period of performance with no maximum funding limit specified. Phase II requires a technology transition and commercialization plan. Phase III addresses dual-use applications for allied military units, civil police, and SWAT organizations.

Phase I technical volumes are capped at 5 pages in 10-point minimum font. Proposers must disclose all foreign nationals or dual citizens involved in the project, complete mandatory Fraud, Waste, and Abuse training, and submit disclosure forms covering telecommunications equipment, foreign affiliations, and funding sources. Failure to submit the required disclosure forms automatically disqualifies an applicant. The government reserves the right to limit awards and withdraw from negotiations. Selection notifications follow within 90 days of the closing date, and debriefings are available upon written request within 30 days of non-selection.

The notice is classified under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and PSC AC12, National Defense R&D Services.

Notice text

DoD SBIR topic CBD234-P001

Component: CBD

Command: CBD

Phase: SBIR Program Phase I Action

Technology Areas: Chem Bio Defense; Materials

Focus Areas: Biotechnology

Keywords: <p>Decontamination; Chemical Warfare Agents; Personnel Decontamination; Casualty Decontamination; Skin Decontamination; Open Wound Decontamination; Chemical Agent Detoxification</p>

ITAR: No

Objective:

The purpose of developing an effective man-portable capability that will rapidly remove chemical warfare agents (CWAs) and other toxic industrial chemicals (TICs) of interest to the U.S. Department of Defense from both intact and wounded human skin, under austere conditions is to bring potentially valuable small business innovations to the Chemical and Biological Defense Program portfolio to discover and develop chemical medical countermeasures (cMCMs) capable of neutralizing CWAs in wounds and on the skin for the treatment of the Warfighter.

Description:

Although decontamination issues have been studied since the onset of chemical warfare, decontamination of chemical warfare agents (CWAs) from the skin remains a thorny problem for a variety of reasons.

 

These include, first and foremost, the ability to rapidly and effectively remove a diversity of toxic chemicals that currently are, or could be, CWAs, without harming or damaging the contaminated skin or wound. Prompt and rapid post-exposure decontamination is critical to reduce the post-exposure effects of CWAs.

 

In addition, a practical decontamination product needs to satisfy a plethora of secondary requirements, which include but are not limited to:

  •  Being simple to use in the field under harsh and likely confusing situations.
  •  Be light weight, compact, and easily stowed in a soldier’s pack.
  •  Be fast acting and effective under a wide range of environmental conditions.
  •  Meet and satisfy Federal Drug Agency (FDA) requirements.
  •  Meet and satisfy major DoD logistical requirements, i.e., long shelf-life, ease of transportation, manufacturability, and cost-effectiveness.
  •  Last, but not least, in addition to removing the toxic agents from skin, the product should be able to detoxify these chemical agents, both while it is being applied on the skin and after its removal. Rapid agent detoxification and decontamination effectiveness are intricately linked because in-situ detoxification is an effective method of reducing agent concentration on the skin before the agent has time to diffuse into the sub-dermal region. Detoxification of the agent also attenuates or prevents secondary contamination of medical or other personnel, and of the environment.

 

Chemical warfare agents (CWAs) are among the most lethal and sinister substances manufactured by man (1). They are designed to kill, maim, immobilize, or psychologically threaten enemy troops.

CWAs can attack the skin which is not only the body’s interface with the outside environment, but also the largest organ of the body, with a surface area of roughly 1.6 m² for women and 1.8 m² for men (6). Skin exposure to warfare agents is also a major problem during non- conventional war (5), or terrorist attack. Over the eons, a wide variety of materials in gas, liquid or solid form have been mobilized for this purpose. At present, CWAs of greatest concern in military operations are relatively low volatility organic liquids that attack the skin (vesicants) or attack the nervous system (nerve agents) (2-4).

 

Human skin, the largest human organ, developed as a physical barrier to the environment (to keep things out) but also maintains the aqueous nature of the human body (to keep things in). Mammalian skin consists of three major layers: stratum corneum, epidermis, and dermis. The stratum corneum, the thin outer layer of keratin-filled dead cells (corneocytes) bounded by densely crosslinked protein and embedded in crystalline lamellar lipids, represents the major barrier protecting the body from loss of internal components and entry of undesirable external materials. The stratum corneum, composed of keratinized dead cells that are continually being replaced, is the first major barrier to chemical agents. The layer underneath the stratum corneum, the epidermis, contains cells that differentiate from viable keratinocytes to corneocytes during their migration from the dermis to the stratum corneum. It also contains a large number of specialized cells. The dermis is the main component of living skin.

 

The purpose of decontamination is to reduce an initial amount of harmful material deposited on the surface of a person or object from the environment to a level that is low enough allow it to continue to safely function. It should be noted that permeability of the contaminant through the surface of the person or object is a complicating issue for any surface decontamination process. Contaminant permeability renders decontamination more difficult to perform, places time limitations on the window of opportunity for its performance.

 

The alternative to decontamination is discarding the object, which in the case of living beings, is not an option.

 

Current skin decontamination methods rely heavily on “wet” decontamination practices, which include washing the body with water, or soap and water (Roul et al., 2017). Alternatively, rapid decontamination makes extensive use of “dry” decontamination, which is based on adsorptive properties of powders, such as activated carbon or Fuller’s Earth (FE) (Roul et al., 2017).

 

Improved personal decontamination methods/products should consider:

  • The effects on both intact skin and open wounds.
  • Impacts on the subsequent wound healing process.
  • Agent variable decontamination efficiency.
  • Post-decontamination CWA detoxification capability. Rapid agent detoxification and decontamination effectiveness are intricately linked because in-situ detoxification is an effective method of reducing agent concentration on the skin before the agent has time to diffuse into the sub-dermal region. Post-decontamination detoxification of the contaminant(s)will also attenuate or prevent secondary contamination of medical or other personnel, and of the environment.

 

There is a clear need to develop an effective man-portable capability that will rapidly remove chemical warfare agents (CWAs) and other toxic industrial chemicals (TICs) of interest to the U.S. Department of Defense from human skin, both intact and wounded, under austere conditions.

Phase I:

A feasibility study to demonstrate the technical and commercial practicality of the concept to include an assessment of its technical readiness and potential applicability to military and commercial markets.

Phase II:

Businesses will produce practical and feasible prototype solutions that can operate in edge and austere environments. Companies will provide a technology transition and commercialization plan for Department of Defense and commercial markets. The DoD will evaluate each product in a realistic field environment and provide solutions to stakeholders for further evaluation. Based on Soldier field assessment, the DoD will request companies to update the previously delivered prototypes to meet final design configuration.

Phase III:

Once the new man-portable skin decontamination capability is developed in Phase II becomes available, it is anticipated that allied military units and civil police and SWAT organizations, both in the U.S. and abroad, will want to adopt the new capability to protect their personnel from harm after exposure CBD or to other toxic materials As the program usage expands and where necessary, new technology enhancements, will need to be developed and tested for both military and civil applications. Government-funded system enhancements are anticipated as further research needs are defined and revised safety standards are promulgated.

Files

File Type Posted
CBD_SBIR_234_R1.PDF PDF
CBD234-P001.pdf PDF

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors